NCT06394414: A Phase 1 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Advanced Solid Tumors |
|
|
| Not yet recruiting | 1 | 162 | RoW | YL201, Serplulimab, Platinum | MediLink Therapeutics (Suzhou) Co., Ltd. | Advanced Solid Tumors | 04/27 | 04/30 | | |
